Analyst Ratings for [RARE] Ultragenyx Pharmaceutical Inc.

6/6/24	Upgrades	Neutral Buy	X
RARE Ultragenyx Pharma Goldman
$56 $67
4/22/24	Initiated	Outperform	X
RARE Ultragenyx Pharma RBC Capital Mkts
$77
12/8/23	Initiated	Overweight	X
RARE Ultragenyx Pharma Wells Fargo
$72
6/14/23	Resumed	Outperform	X
RARE Ultragenyx Pharma Credit Suisse
$96
6/6/23	Upgrades	In-line Outperform	X
RARE Ultragenyx Pharma Evercore ISI
$60 $80
4/26/23	Initiated	Overweight	X
RARE Ultragenyx Pharma Cantor Fitzgerald
$114
1/18/23	Resumed	Buy	X
RARE Ultragenyx Pharma Canaccord Genuity
$90
12/30/22	Resumed	Buy	X
RARE Ultragenyx Pharma H.C. Wainwright
$82
11/3/22	Upgrades	Neutral Outperform	X
RARE Ultragenyx Pharma Robert W. Baird
$50
10/13/22	Upgrades	Neutral Buy	X
RARE Ultragenyx Pharma Guggenheim
$50
8/1/22	Downgrades	Outperform In-line	X
RARE Ultragenyx Pharma Evercore ISI
$95 $60
3/16/22	Upgrades	Neutral Outperform	X
RARE Ultragenyx Pharma Credit Suisse
$99 $105
2/11/22	Upgrades	Neutral Overweight	X
RARE Ultragenyx Pharma JP Morgan
$132
7/15/21	Initiated	Neutral	X
RARE Ultragenyx Pharma Guggenheim
6/29/21	Upgrades	Neutral Buy	X
RARE Ultragenyx Pharma BofA Securities
$162
6/4/21	Resumed	Neutral	X
RARE Ultragenyx Pharma Robert W. Baird
$109
5/6/21	Upgrades	Neutral Buy	X
RARE Ultragenyx Pharma Citigroup
$160 $151
5/6/21	Upgrades	In-line Outperform	X
RARE Ultragenyx Pharma Evercore ISI
$144
4/26/21	Resumed	Neutral	X
RARE Ultragenyx Pharma Credit Suisse
$99
3/2/21	Resumed	Buy	X
RARE Ultragenyx Pharma Stifel
$179
2/12/21	Downgrades	Overweight Neutral	X
RARE Ultragenyx Pharma JP Morgan
$165
8/2/19	Resumed	Outperform	X
RARE Ultragenyx Pharma Wedbush
$75
3/27/19	Upgrades	Eq-Weight Overweight	X
RARE Ultragenyx Pharma Morgan Stanley
$68 $83
2/22/19	Resumed	Outperform	X
RARE Ultragenyx Pharma Raymond James
$80
1/2/19	Downgrades	Outperform Mkt Perform	X
RARE Ultragenyx Pharma Raymond James
11/8/18	Upgrades	Sell Neutral	X
RARE Ultragenyx Pharma Citigroup
9/10/18	Initiated	Equal-Weight	X
RARE Ultragenyx Pharma Morgan Stanley
$92
6/21/18	Downgrades	Outperform Neutral	X
RARE Ultragenyx Pharma Credit Suisse
5/11/18	Upgrades	Eq Weight Overweight	X
RARE Ultragenyx Pharma Barclays
$62 $74
5/10/18	Initiated	Neutral	X
RARE Ultragenyx Pharma Goldman
$63
4/18/18	Upgrades	Hold Buy	X
RARE Ultragenyx Pharma SunTrust
3/22/18	Resumed	Overweight	X
RARE Ultragenyx Pharma Piper Jaffray
$67
2/21/18	Reiterated	Buy	X
RARE Ultragenyx Pharma Stifel
$85 $74

RARE Ultragenyx Pharmaceutical Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.